| Followers | 153 |
| Posts | 50383 |
| Boards Moderated | 0 |
| Alias Born | 02/27/2012 |
Tuesday, January 10, 2017 9:51:18 AM
Lol, swamp interesting that happened almost the moment I made that post, lets hope it can continue and move well above .01!
Recent PPCB News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/31/2026 10:12:48 AM
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/19/2026 09:30:42 PM
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy • GlobeNewswire Inc. • 03/12/2026 12:45:00 PM
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study • GlobeNewswire Inc. • 03/10/2026 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/06/2026 10:22:19 PM
- Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors • IH Market News • 03/03/2026 03:34:06 PM
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models • GlobeNewswire Inc. • 03/03/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:19:30 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/25/2026 05:15:10 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/19/2026 10:28:16 PM
- Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results • GlobeNewswire Inc. • 02/18/2026 01:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 07:54:17 PM
- Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market • GlobeNewswire Inc. • 02/05/2026 01:45:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2026 10:29:59 PM
- Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations • GlobeNewswire Inc. • 01/27/2026 01:45:00 PM
- Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia • GlobeNewswire Inc. • 01/20/2026 01:45:00 PM
- Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer • GlobeNewswire Inc. • 01/15/2026 01:45:00 PM
- Propanc Biopharma Provides Shareholder Update • GlobeNewswire Inc. • 01/13/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2026 10:00:52 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/29/2025 10:13:52 PM
- Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal • GlobeNewswire Inc. • 12/22/2025 12:00:00 PM
- When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology • AllPennyStocks.com • 12/22/2025 11:45:00 AM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/10/2025 10:24:13 PM
